Does Rallies track congressional trades in ABT?

Yes. Rallies tracks politician and congressional stock disclosures for ABT, including reported purchases, sales, dates, owners, and trade amounts when available.

Is ABT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABT. It does not provide personalized investment advice.

ABT (Abbott Laboratories) Stock Analysis - Politician Trades

Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of May 20, 2026, ABT trades at $88.23 with a market cap of $153.12B and a P/E ratio of 24.68. ABT moved -0.53% today. Year to date, ABT is -28.48%; over the trailing twelve months it is -34.47%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $120.24. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded ABT stock?

Recent politician trading activity in ABT includes disclosures from Laura Friedman, Michael McCaul, Gilbert Cisneros, Thomas H. Kean, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

ABT Key Metrics

Key financial metrics for ABT
Metric	Value
Price	$88.23
Market Cap	$153.12B
P/E Ratio	24.68
EPS	$3.59
Dividend Yield	0.63%
52-Week High	$141.23
52-Week Low	$81.97
Volume	5.95M
Avg Volume	0
Revenue (TTM)	$45.13B
Net Income	$6.28B
Gross Margin	56.26%

Congressional Trades in ABT

Laura Friedman exchange ABT on Mar 24, 2026 (amount: $15.00K).
Michael McCaul sale ABT on Mar 4, 2026 (amount: $15.00K) for Spouse.
Gilbert Cisneros sale ABT on Feb 10, 2026 (amount: $15.00K).
Thomas H. Kean purchase ABT on Jan 29, 2026 (amount: $15.00K).
Julie Johnson sale ABT on Dec 18, 2025 (amount: $15.00K) for Joint.

Latest ABT News

Abbott’s Dividend Yield Hits Near-Decade High, Attracts Income Investors — May 12, 2026
Analyst Sees Abbott Undervaluation, Flags Recall Costs and China Slowdown as Temporary — May 9, 2026
Augment Acquires Merlin, Brings Alex Moazed Into $8 Trillion Distribution Market — Apr 29, 2026
Abbott's Ablation Catheter Posts 87% Arrhythmia-Free Rate, UltiSynq Lead Hits 99% Pacing Success — Apr 25, 2026
Coagulation Analyzer Market to Reach $7.87B by 2035 with 5.55% CAGR — Apr 22, 2026

Recent ABT Insider Trades

STARKS DANIEL J bought 10.00K (~$926.54K) on Apr 27, 2026.
Boudreau Philip P bought 2.20K (~$201.30K) on Apr 23, 2026.
Shroff Eric sold 709 (~$81.95K) on Mar 2, 2026.

ABT Analyst Consensus

20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $120.24.

Common questions about ABT

Which politicians traded ABT stock?: Recent politician trading activity in ABT includes disclosures from Laura Friedman, Michael McCaul, Gilbert Cisneros, Thomas H. Kean, and Julie Johnson. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ABT?: Yes. Rallies tracks politician and congressional stock disclosures for ABT, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ABT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABT. It does not provide personalized investment advice.